250 related articles for article (PubMed ID: 22205997)
1. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.
Kodama T; Togawa T; Tsukimura T; Kawashima I; Matsuoka K; Kitakaze K; Tsuji D; Itoh K; Ishida Y; Suzuki M; Suzuki T; Sakuraba H
PLoS One; 2011; 6(12):e29074. PubMed ID: 22205997
[TBL] [Abstract][Full Text] [Related]
2. Composition of gangliosides and neutral glycosphingolipids of brain in classical Tay-Sachs and Sandhoff disease: more lyso-GM2 in Sandhoff disease?
Rosengren B; Månsson JE; Svennerholm L
J Neurochem; 1987 Sep; 49(3):834-40. PubMed ID: 3612128
[TBL] [Abstract][Full Text] [Related]
3. In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.
Sinici I; Yonekawa S; Tkachyova I; Gray SJ; Samulski RJ; Wakarchuk W; Mark BL; Mahuran DJ
PLoS One; 2013; 8(3):e57908. PubMed ID: 23483939
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis.
Matsuoka K; Tamura T; Tsuji D; Dohzono Y; Kitakaze K; Ohno K; Saito S; Sakuraba H; Itoh K
Mol Ther; 2011 Jun; 19(6):1017-24. PubMed ID: 21487393
[TBL] [Abstract][Full Text] [Related]
6. Assay of the GM2-ganglioside cleaving hexosaminidase activity of skin fibroblasts for GM2-gangliosidoses.
Harzer K
Clin Chim Acta; 1983 Nov; 135(1):89-93. PubMed ID: 6228344
[No Abstract] [Full Text] [Related]
7. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
8. A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.
Hou Y; McInnes B; Hinek A; Karpati G; Mahuran D
J Biol Chem; 1998 Aug; 273(33):21386-92. PubMed ID: 9694901
[TBL] [Abstract][Full Text] [Related]
9. Plasma G
Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
[TBL] [Abstract][Full Text] [Related]
10. Characterization of inducible models of Tay-Sachs and related disease.
Sargeant TJ; Drage DJ; Wang S; Apostolakis AA; Cox TM; Cachón-González MB
PLoS Genet; 2012 Sep; 8(9):e1002943. PubMed ID: 23028353
[TBL] [Abstract][Full Text] [Related]
11. Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards.
Chamoles NA; Blanco M; Gaggioli D; Casentini C
Clin Chim Acta; 2002 Apr; 318(1-2):133-7. PubMed ID: 11880123
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.
Mark BL; Mahuran DJ; Cherney MM; Zhao D; Knapp S; James MN
J Mol Biol; 2003 Apr; 327(5):1093-109. PubMed ID: 12662933
[TBL] [Abstract][Full Text] [Related]
13. Ganglioside loading of cultured fibroblasts: a provocative method for the diagnosis of the GM2 gangliosidoses.
Charrow J; Binns HJ
Clin Chim Acta; 1986 Apr; 156(1):41-9. PubMed ID: 2938852
[TBL] [Abstract][Full Text] [Related]
14. Classification of disorders of GM2 ganglioside hydrolysis using 3H-GM2 as substrate.
Novak A; Callahan JW; Lowden JA
Biochim Biophys Acta; 1994 Mar; 1199(2):215-23. PubMed ID: 8123671
[TBL] [Abstract][Full Text] [Related]
15. [Recent advances in molecular genetics of GM2 gangliosidosis].
Wakamatsu N
Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
[TBL] [Abstract][Full Text] [Related]
16. GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
Demir SA; Timur ZK; Ateş N; Martínez LA; Seyrantepe V
J Neuroinflammation; 2020 Sep; 17(1):277. PubMed ID: 32951593
[TBL] [Abstract][Full Text] [Related]
17. Specificity of mouse GM2 activator protein and beta-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2.
Yuziuk JA; Bertoni C; Beccari T; Orlacchio A; Wu YY; Li SC; Li YT
J Biol Chem; 1998 Jan; 273(1):66-72. PubMed ID: 9417048
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling.
Myerowitz R; Lawson D; Mizukami H; Mi Y; Tifft CJ; Proia RL
Hum Mol Genet; 2002 May; 11(11):1343-50. PubMed ID: 12019216
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain.
Neuenhofer S; Conzelmann E; Schwarzmann G; Egge H; Sandhoff K
Biol Chem Hoppe Seyler; 1986 Mar; 367(3):241-4. PubMed ID: 3707714
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
Kobayashi T; Goto I; Okada S; Orii T; Ohno K; Nakano T
J Neurochem; 1992 Oct; 59(4):1452-8. PubMed ID: 1402895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
